Wegovy® (semaglutide) is a prescription medicine for chronic weight management, and the thigh is one of the three places it can be injected. If you are wondering exactly where in the thigh the injection goes, how deep it goes, or whether the thigh works better than the stomach or the arm, this guide answers those questions using the current FDA prescribing information and the manufacturer’s own pen instructions.
The short answer to the question most people are really asking: the site does not change how well the medicine works. Semaglutide reaches the bloodstream in the same way from the abdomen, the thigh or the upper arm, so the thigh is a matter of comfort and routine, not potency. What does matter is that the injection goes into the fat layer just under the skin, not into muscle, and that you know how much to take and when — the semaglutide weight-loss dosage chart covers the schedule in detail.
This page was fully reviewed in September 2026 and updated for the February 2026 label, the higher-dose Wegovy® HD 7.2 mg injection approved in March 2026, and the Wegovy® pill approved in December 2025.
Wegovy® is semaglutide, a GLP-1 receptor agonist. It copies a hormone your body makes after eating, binding to receptors that influence hunger and fullness, so you feel satisfied on less food. It is prescribed alongside a reduced-calorie diet and increased physical activity, not instead of them.
The thigh is a popular site for a practical reason: it is easy to see and easy to reach with either hand. Wegovy® is a subcutaneous injection, which means it goes into the layer of fat between the skin and the muscle, and the front of the thigh reliably has that layer. Think of the fat layer as a slow-release sponge — the medicine sits there and is absorbed steadily over the following days, which is exactly what a once-weekly medicine is designed to do. Injecting into muscle is not how this medicine is meant to be given.
Wegovy® is a long-term treatment used under medical supervision. Before starting, your prescriber should review your full medical history and every medicine you take, and you will have follow-up visits to check your progress and how well you are tolerating each dose.
No. This is the question behind most searches for the “best” injection site, and the prescribing information answers it plainly: “Similar exposure was achieved with subcutaneous administration of semaglutide in the abdomen, thigh, or upper arm,” and the label adds that the time of day and the injection site can be changed without a dose adjustment.
In plain terms: the three sites are three doors into the same room. Choose the door you can open most easily every week. If your thigh is comfortable and easy to reach, that is the right site for you — you are not giving anything up by choosing it.
| Approved site | Where exactly | Practical notes |
|---|---|---|
| Thigh | Front or outer front of the upper leg, roughly a hand’s width below the hip and a hand’s width above the knee | Easy to see, easy to reach with either hand, usually has a good fat layer while seated |
| Abdomen | Lower stomach, at least 2 inches away from the belly button | The most commonly used site; avoid the area right around the navel |
| Upper arm | Back or outer part of the upper arm | Same absorption, but many people find it awkward to reach on themselves |
The steps below describe the single-dose Wegovy® pen used in the United States, which is an autoinjector with an integrated 29-gauge needle that stays hidden. You do not attach a needle, you do not prime it, and there is no plunger or button to press. Always follow the Instructions for Use that come in your carton and the training your own prescriber or pharmacist gives you.
If your pen looks different: outside the United States — in Canada, for example — Wegovy® is also supplied in a multi-dose FlexTouch® pen that holds four weekly doses and does take a new disposable needle for each injection, with the needle removed afterwards. That is why online instructions disagree with each other. Use the instructions that came with the pen in your hand.
Aim for the fleshy front or outer front of the upper leg, roughly a hand’s width below your hip and a hand’s width above your knee. Sitting down makes this easier to judge, because the fat layer is more obvious when the muscle is relaxed.
Avoid skin that is bruised, tender, hard, scarred, covered by a rash, or marked by stretch marks, and stay away from the inner thigh where skin is thinner. You may use the same thigh week after week — the manufacturer’s guidance is that you can use the same body area, just not the exact same spot — so many people move around the thigh in a small square or clock pattern, a couple of inches at a time.
Wegovy® is injected once a week, on the same day each week, with or without food. You can change which day you inject as long as your last dose was at least 2 days (48 hours) earlier.
The dose is raised in steps so your body can adjust. The starting dose is not a weight-loss dose — it is there for tolerance.
| Dose (once weekly) | When | Notes |
|---|---|---|
| 0.25 mg | Weeks 1–4 | Starting dose, for tolerance |
| 0.5 mg | Weeks 5–8 | |
| 1 mg | Weeks 9–12 | |
| 1.7 mg | Weeks 13–16 | |
| 2.4 mg | Week 17 onward | Standard maintenance dose |
| 7.2 mg (Wegovy® HD) | After at least 4 weeks at 2.4 mg | Approved March 2026 for adults who need additional weight loss |
Your prescriber may move more slowly than this schedule, or hold you at a lower dose, depending on side effects and results. Every dose uses the same pen design and the same three injection sites.
Wegovy® HD is a higher-strength version of the same weekly injection, approved by the FDA in March 2026 and available in pharmacies from April 2026. In its trial it produced about 21% average weight loss over 72 weeks in people who stayed on treatment, compared with about 18% for the 2.4 mg dose, and roughly one in three participants lost 25% or more of their body weight.
One side effect became noticeably more common at the higher dose: dysesthesia, meaning altered skin sensation such as tingling, burning or an odd sensitivity to touch. It was reported by about 22% of people on Wegovy® HD, 6% on the 2.4 mg dose and 0.3% on placebo. It is a dose-related effect of the medicine, not a sign that something went wrong with your injection or your injection site — but it is worth telling your prescriber about.
The rule is based on hours, not days off the calendar:
Setting a weekly phone reminder, or tying the injection to something you already do every week, is the simplest way to stay on schedule. Consistency matters more for this medicine than the exact hour of the day.
Reactions at the injection site itself are usually minor: pain, redness, swelling, itching or bruising that settles within a day or two. Moving to a different spot each week gives the skin time to recover. A small, soft lump under the skin straight after the injection is normal and usually gone within hours.
The more common side effects are digestive rather than local — nausea, diarrhea, constipation, vomiting and abdominal pain — and they tend to be worst in the days after a dose increase, then ease as your body adjusts.
Serious side effects are less common but important to recognize. Wegovy® carries a boxed warning about thyroid C-cell tumors seen in rodents, and it must not be used by anyone with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The label also warns about pancreatitis, gallbladder disease, low blood sugar, kidney injury from dehydration, severe gastrointestinal reactions, allergic reactions, diabetic retinopathy complications in people with type 2 diabetes, an increase in heart rate, and the risk of stomach contents entering the lungs during general anesthesia or deep sedation.
Get medical help promptly for severe or persistent abdominal pain, ongoing vomiting, signs of an allergic reaction, or any sudden change in vision. Sudden vision changes have been discussed widely in connection with this drug class; IAPAM covers that question separately in Ozempic® and Wegovy® blindness: truth or myth.
Yes. The abdomen and the upper arm are both approved, and the technique is identical at all three sites. What you are looking for is a spot where there is a comfortable layer of fatty tissue under the skin — not muscle, not a vein, and not skin that is irritated, hardened or scarred.
Switching sites is a reasonable response to discomfort or bruising in one area, and it costs you nothing in effectiveness. If you are struggling with results rather than with the injection itself, the issue is usually dose, timing or habits rather than location — there are practical ways to increase weight loss on Wegovy® that address that directly, and it is also worth understanding how Wegovy® compares with Zepbound® if you and your prescriber are weighing options.
With an autoinjector, the pen does most of the confirming for you. The signs of a properly given dose are:
Contact your prescriber if a hard lump stays for more than a day or two, if the site becomes increasingly red, swollen, warm or painful, or if you are not confident the full dose was delivered. Do not take a second dose to make up for one you are unsure about — ask first.
If you use a multi-dose FlexTouch® pen outside the US, the storage rules differ: it is kept for a set number of weeks after first use and stored with the needle removed. Check the leaflet in your carton.
In December 2025 the FDA approved a Wegovy® pill — the first oral GLP-1 for weight management — which changes the conversation for people who dislike needles. It starts at 1.5 mg once daily and steps up every 30 days to a 25 mg maintenance dose.
The pill comes with timing rules the injection does not have. It is taken first thing in the morning on an empty stomach, swallowed whole with no more than 4 oz of water, and then nothing to eat, drink or swallow — including other medicines — for at least 30 minutes. If that routine does not fit your morning, a weekly injection may still be the more practical option. For more on how oral and injectable semaglutide differ, see IAPAM’s comparison of oral versus injectable semaglutide.
Average weight loss in company-reported trials
Injection figures are from the 72-week STEP UP trial and the pill figure from the 64-week OASIS 4 trial, each counting all participants regardless of whether they stayed on treatment. These were separate studies, not a head-to-head comparison, so treat the gap between them as an indication rather than a measured difference.
Tell your prescriber about every medicine, supplement, vitamin and herbal product you take before you start, and about anything new you add later. Three interactions matter most:
This is not a complete list of interactions. Your pharmacist can check your full medicine list against Wegovy® in a couple of minutes.
If you started this medicine a year or two ago, several things are different now:
For prescribers and clinical staff running a medical weight management program, the injection-teaching visit is where most avoidable follow-up calls are prevented. A short, repeatable protocol covers it:
Clinics building or formalizing this kind of program can develop the clinical and operational side through IAPAM’s GLP-1 certification training, which covers patient selection, titration, monitoring and program design for medical weight management.
Get self-paced access to a real IAPAM Botox® module — watch step-by-step injection technique, follow along with our physician instructors, and claim 1 AMA PRA Category 1 CME when you finish.
What’s Inside Your Free Module
Eligibility: MD/DO, NP, APRN/CRNA, PA, DMD/DDS, RN
Enter your details and we’ll email your access link.
There is no single best site. The FDA prescribing information states that similar semaglutide exposure was achieved with subcutaneous injection in the abdomen, thigh or upper arm, and that the injection site can be changed without any dose adjustment. The best site is the one you can reach comfortably and use consistently.
Yes. The upper arm is one of the three approved sites, along with the thigh and the abdomen. Many people find the back of the upper arm hard to reach on themselves, which is why the thigh and abdomen are used more often. Absorption is the same at all three sites.
Not in the United States. The US Wegovy® pen is a single-dose autoinjector with a 29-gauge needle already built in and hidden, and it does not need to be primed. Multi-dose FlexTouch® pens used in Canada and some other countries do take a separate needle for each injection.
If your next scheduled dose is more than 2 days (48 hours) away, take the missed dose as soon as you can. If it is less than 2 days away, skip it and go back to your regular day. Never take two doses close together. If you have missed 2 weeks or more, contact your prescriber before restarting.
They have not been compared head to head. In its own trial the 25 mg Wegovy® pill produced about 14% average weight loss over 64 weeks counting all participants, while the 2.4 mg injection produced about 16% and the 7.2 mg Wegovy® HD injection about 19% over 72 weeks in a separate trial. The pill also has strict timing rules: empty stomach, no more than 4 oz of water, nothing to eat, drink or swallow for 30 minutes.
Yes. The abdomen (at least 2 inches away from the belly button) and the upper arm are both approved. Avoid skin that is scarred, bruised, tender, hardened or covered by a rash, and avoid injecting into muscle or a vein.
A US Wegovy® pen is stored in the refrigerator at 36°F to 46°F, and it can be kept in its original carton at 46°F to 86°F for up to 28 days. It must never be frozen, and a pen that has been frozen should not be used.
The thigh is a convenient, approved place to inject Wegovy®, and choosing it costs you nothing in results. What matters is the layer you inject into — the fat just under the skin, never muscle — along with a consistent weekly day, a fresh spot each week, correct storage, and a prescriber who is monitoring your dose and your progress.
For physicians, nurse practitioners and clinical teams adding medical weight management to their practice, IAPAM has trained more than 15,000 providers over 20 years. Our GLP-1 certification program covers patient selection, titration, monitoring and the operational side of running the service.
Explore GLP-1 Certification Training
Sources:
WEGOVY® (semaglutide) injection, US Prescribing Information, revised February 2026 — US Food and Drug Administration.
Wegovy® Pen Guide, Dosing Information and FAQs — Novo Nordisk (wegovy.com); The Wegovy® Pen and Pill — Novo Nordisk (novomedlink.com).
WEGOVY® Canadian Product Monograph, December 2025 — Novo Nordisk Canada.
“FDA approves Novo Nordisk’s new Wegovy® HD injection,” March 19, 2026, and “FDA approves Novo Nordisk’s Wegovy® pill,” December 22, 2025 — Novo Nordisk.
FDA Drug Safety Communication, January 13, 2026 — removal of the suicidal behavior and ideation warning from GLP-1 receptor agonist labels.
Disclaimer: This guide is for informational and educational purposes only and does not constitute medical advice. Always follow the Instructions for Use supplied with your medicine and the guidance of your own prescriber. Dosing, injection technique and monitoring must be tailored to each patient by a qualified, licensed provider.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.